Aurinia Pharmaceuticals (AUPH) Equity Average (2018 - 2026)

Aurinia Pharmaceuticals has reported Equity Average for 9 years, with the latest figure at $574.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 57.9% year-over-year to $574.5 million; the trailing twelve-month figure through Mar 2026 stood at $574.5 million (up 57.9% YoY), and the FY2025 full-year result was $479.4 million, up 26.92% from the prior year.
• Equity Average for Q1 2026 stood at $574.5 million, up from $473.6 million in the prior quarter.
• The five-year high for Equity Average was $574.5 million in Q1 2026, with the low at $342.7 million in Q2 2025.
• Historically, Equity Average has averaged $405.8 million across 5 years, with a median of $391.3 million in 2023.
• Annual changes were most pronounced in 2023 — Equity Average dropped 14.17% — and 2026, when it surged 57.9%.
• Aurinia Pharmaceuticals' Equity Average stood at $414.4 million in 2022, then decreased by 7.12% to $384.9 million in 2023, then decreased by 0.57% to $382.7 million in 2024, then gained by 23.73% to $473.6 million in 2025, then climbed by 21.31% to $574.5 million in 2026.
• The last three Equity Average figures came in at $574.5 million (Q1 2026), $473.6 million (Q4 2025), and $350.5 million (Q3 2025), per Business Quant data.